4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Retained Earnings of -$785.1 million for Q1 2026, down 25.78% year-over-year from -$1.1 billion in Q1 2025, and down 9.6% quarter-over-quarter from -$716.3 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Retained Earnings for 7 consecutive years, with -$785.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 25.78% year-over-year to -$785.1 million; the TTM figure through Mar 2026 stood at -$785.1 million (down 25.78% YoY), while the FY2025 annual figure was -$716.3 million, down 24.32% from the prior year.
- Retained Earnings eased to -$785.1 million in Q1 2026 per FDMT's latest filing, from -$716.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $534000.0 in Q3 2023 and bottomed at -$785.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$372.4 million across 5 years, with a median of -$372.8 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings surged 100.19% — and 2025, when it tumbled 572560.55%.
- 4D Molecular Therapeutics' Retained Earnings stood at -$314.5 million in 2022, then plunged by 32.06% to -$415.3 million in 2023, then sank by 38.73% to -$576.2 million in 2024, then declined by 24.32% to -$716.3 million in 2025, then retreated by 9.6% to -$785.1 million in 2026.
- Business Quant data shows FDMT's Retained Earnings at -$785.1 million in Q1 2026, -$716.3 million in Q4 2025, and -$735.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -858.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -858.00 Mn |
| Mar 31, 2026 | -785.10 Mn |
| Dec 31, 2025 | -716.30 Mn |
| Sep 30, 2025 | -735.70 Mn |
| Jun 30, 2025 | 337,000.00 |
| Mar 31, 2025 | -624.20 Mn |
| Dec 31, 2024 | -576.20 Mn |
| Sep 30, 2024 | -526.52 Mn |
| Jun 30, 2024 | -482.70 Mn |
| Mar 31, 2024 | -109,000.00 |
| Dec 31, 2023 | -415.33 Mn |
| Sep 30, 2023 | 534,000.00 |
| Jun 30, 2023 | -372.79 Mn |
| Mar 31, 2023 | -270,000.00 |
| Dec 31, 2022 | -314.49 Mn |
| Sep 30, 2022 | -287.10 Mn |
| Jun 30, 2022 | -261.42 Mn |
| Mar 31, 2022 | -233.30 Mn |
| Dec 31, 2021 | -207.00 Mn |
| Sep 30, 2021 | -195,000.00 |